RESEARCH

Efficacy and safety of wait and see strategy versus radical surgery and local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy: a metaanalysis

Guo-hua Zhao¹⁺, Li Deng²⁺, Dong-man Ye³, Wen-hui Wang³, Yan Yan³ and Tao Yu^{3*}

Abstract

Background: Neoadjuvant therapy can shrink tumors, increase anus preservation rate, and protect anal function. Radical surgery need cut off the diseased bowel, clean up the lymph nodes, and then restore bowel function. It could bring traumatic effect and poor postoperative quality of life to the patient. Local resection requires removal of the diseased bowel with circular negative margin. The surgical trauma is small, and the postoperative quality of life is good. In this meta-analysis, we aimed to evaluate the efficacy and safety between wait and see strategy (WS), radical surgery (RS), and local excision (LE) of rectal cancer patients with clinical complete response (cCR) response after neoadjuvant chemoradiotherapy.

Methods: We searched PubMed, Cochrane Library, CNKI (China National Knowledge Infrastructure), and Wanfang databases to compare wait and see strategy with radical surgery and local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy up to March 2020. We collected the data of local recurrence, distant metastasis, cancer-related death, overall survival, and disease-free survival and used RevMan 5.0 to carry out the meta-analysis. Continuous data were evaluated by the standardized mean differences (SMD) with 95% confidence intervals (95% CIs), and dichotomous data were evaluated by relative risks (ORs or RRs) with 95% CIs. We aimed to compare the advantages and disadvantages of the three groups.

Results: Eleven English studies with 1131 patients were included. There were 412 patients in WS group, 678 patients in RS group, and 41 patients in LE group. WS group had a higher local recurrence rate than RS group (OR 7.32, 95% CI 3.58 to 14.95, P < 0.001). There was no significant difference in the other data between the three groups.

(Continued on next page)

* Correspondence: yutao611482@sina.com

[†]Guohua Zhao, the first author and Li Deng, the co-first author ³Department of Medical Imaging, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No 44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, PR China Full list of author information is available at the end of the article



[©] The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.





(Continued from previous page)

Conclusion: Compared with the RS group, the WS group had an increased risk of local recurrence. However, the WS group had a similar DFS and OS compared with the RS group and the local excision group. Hence, we speculated that the WS group would have similar results as the surgery group for patients with cCR status.

Keywords: Wait and see, Radical surgery, Local excision, cCR, Meta-analysis

Background

Colorectal cancer is a serious threat to human health. Mid-low rectal cancer accounts for 70% of colorectal cancer [1, 2]. Radical surgery (RS) remains the main treatment for mid-low rectal cancer [3, 4]. However, 10-20% of patients still have local recurrence after radical surgery [5, 6]. Neoadjuvant chemoradiotherapy has reduced the local recurrence rate of patients and can preserve the anus. Approximately 20% of rectal cancer patients have a good response to neoadjuvant chemoradiotherapy (NCRT). If NCRT (50.4 Gy/25 and capecitabine) is performed, surgery should be extended approximately 6-12 weeks. The tumor can shrink to a minimum size and even disappear completely after neoadjuvant chemoradiotherapy [7]. Approximately 10-20% of patients can achieve a clinical complete response (cCR) [8]. The stringent definition of cCR was proposed by Mass in 2012, and it contained five diagnostic criteria [9]. The diagnostic criteria of cCR were no residual tumor and white scar in endoscopy, negative biopsies from the white scar, no palpable tumor with digital rectal exam (DRE), no suspicious lymph nodes in MRI, and substantial downsizing with no residual tumor or residual fibrosis in MRI [10]. In our opinion, the most critical points in adopting the wait and see strategy (WS) strategy are no residual tumor in endoscopy and no suspicious lymph nodes or residual tumor in MRI.

In 2004, Habr-Gama published the results of rectal cancer patients with cCR status after neoadjuvant chemoradiotherapy. Habr-Gama first proposed the WS strategy of treating rectal cancer patients with cCR status and pointed out that the WS strategy could achieve similar clinical effects as surgery [11]. The 5-year DFS and OS rates of cCR status were 92% and 100%, respectively. The 5-year disease-free and 5-year overall survival rates of the radical surgery group were 83% and 88%, respectively. No significant differences were found between the two groups. Nowadays, there are three routine treatments for patients with cCR status: they are WS strategy, radical surgery, and local resection. WS strategy has no invasive operations to the tumor, no surgical trauma, and no change in intestinal function, which ensures the good quality of life of patients. Radical surgery mainly follow the total mesorectal excision (TME) principle, where it needs to remove 15 cm bowel from the upper edge of the tumor and 3-5 cm from the lower edge, with the corresponding lymph nodes. After radical surgery, there may be some changes in bowel function with increased stool frequency and decreased sexual function. And some patients may have loose anus. It could bring physical and psychological trauma to the patients. Local excision only cut off the tumor and the surrounding normal tissues to ensure negative margins, and it could ensure the continuity of the intestine and would not have a significant impact on bowel function and quality of life. The details of specific resection range are in additional file 8.

There were several meta-analyses related to this topic, such as Li's research, Dossa's research, and some other papers published in a Chinese magazine [12–14]. The disease-free survival (HR 0.56, 95% CI 0.20–1.60) and overall survival (HR 3.91, 95% CI 0.57–26.72) of Dossa's research are similar to those of Li. Our study included more studies and more patients to explore the efficacy and safety of the wait and see strategy versus those of surgery for rectal cancer with cCR response after neoad-juvant chemoradiotherapy. We also performed a meta-analysis to compare the efficacy and safety of the WS strategy versus those of radical surgery and those of WS strategy versus those of local resection (LE).

Methods

Literature search

We carried out this meta-analysis by using the PRISMA guidelines. The details of PICOS were as follows: Population: rectal cancer patients with a cCR response after neoadjuvant chemoradiotherapy; Intervention: wait and see strategy; Comparator: radical surgery or local excision; Outcomes: long-term outcomes including local recurrence, distant metastasis, cancer-related death, disease-free survival (DFS), and overall survival (OS) which were analyzed and compared (additional file 3). Continuous data were evaluated by the standardized mean differences (SMD) with 95% confidence intervals (95% CIs), and dichotomous outcomes were evaluated by relative risks (ORs or RRs) with 95% CIs.

We searched the Cochrane Library, PubMed, CNKI (China National Knowledge Infrastructure), and Wanfang databases (up to March 2020). Articles about wait and see versus radical surgery or local excision after neoadjuvant chemoradiotherapy for rectal cancer were collected. To avoid missing useful articles, we expanded the scope of search terms and find articles for the purpose by manual screening. The search terms were "wait and see" or "nonoperative management" and "neoadjuvant chemoradiotherapy" and "rectal cancer." The details are shown in additional file 1.

Inclusion and exclusion criteria

There were 4 inclusion criteria: (1) pathological and longterm outcomes were compared between wait and see and radical surgery or local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy; (2) surgery included radical surgery and local excision; (3) cCR response after neoadjuvant chemoradiotherapy (criteria for ccR were mentioned above) [15]; and (4) RCT (randomized Controlled Trial), RCNTs (retrospective comparative nonrandomized studies), PCNTs (prospective comparative non-randomized studies), cohort studies, or case-control studies. The details of diagnostic criteria of all studies are shown in Table 1. The details of diagnostic criteria of each method in each study are shown in additional file 2.

There were 3 exclusion criteria: (1) studies with no valuable outcome; (2) patients were not well grouped or groups were confusing and not suitable for the purpose of the article; and (3) bad clinical response of rectal cancer after neoadjuvant chemoradiotherapy. Bad clinical response included larger residual tumor in endoscopy and DRE, positive biopsies, and larger tumor and lymph nodes in MRI. The details of inclusion and exclusion criteria are in additional file 6.

Data extraction and quality control

Using the Newcastle-Ottawa Scale (NOS) guidelines, two reviewers searched the literatures (GHZ and DMY) independently [26]. We collected the useful data, as shown in Tables 1, 2, 3, and 4. Table 1 contains the baseline data of related studies. Table 2 contains the initial tumor stages of the included patients. Table 3 contains the tumor staging after including neoadjuvant therapy. Table 4 contains the primary and secondary objectives. The primary objectives include local recurrence (LE), distant metastasis (DM), and cancer-related death (CRD). The secondary objectives include disease-free survival (DFS) and overall survival (OS). More basic information of patients and the details of neoadjuvant treatment plans are in additional file 4 and additional file 5. A third reviewer had the final decision power to resolve the disagreements of the study. We tried to contact the authors with missing data, but did not get any relevant data.

Statistical analysis

We used RevMan 5.0 to carry out the meta-analysis. Continuous data were evaluated by the standardized mean differences (SMD) with 95% confidence intervals (95% CIs), and dichotomous data were evaluated by relative risks (ORs or RRs) with 95% CIs. Heterogeneity and publication bias were estimated by I^2 statistic and funnel plots separately. When huge heterogeneity existed ($I^2 \ge 50\%$), we used random-effects models to analyze the data. We used fixed-effects model to analyze the data with little heterogeneity ($I^2 < 50\%$).

Results

Study selection

Duplicated records were deleted. We deleted 1843 studies after reading the titles and abstracts carefully. Deleted studies were due to not of rectal cancer (n = 527), no control group (n = 851), and insufficient data (n = 455). Regarding study information, after we read the remaining studies carefully, 11 English studies with 1131 patients were included [11, 16–25]. There were 412 patients in the WS group, 678 patients in the RS group, and 41 patients in the LE group. There were 6 Eastern studies and 5 Western studies in the meta-analysis. There were 10 English studies, and 1 was a Chinese study. The Western research included European, American, and Latin American research, while the Eastern research mainly included Asian research. Yeom and Lai reported local resection for rectal cancer with cCR response after neoadjuvant chemoradiotherapy. Some baseline data from the articles were inconsistent, which could affect the results. We deleted several articles and hoped to reduce the bias caused by inconsistent baseline data. Patient information: the clinical stages of included patients were stages I to III. Approximately 81.9% of patients were at the beginning T3-4 and 67.8% N1-2 (Table 2). A total of 19.4% of patients were ypT3-T4 and 11.8% of patients were ypN1-2, and we divided the surgery group into RS (radical surgery) and LE (local excision). The clinical staging of included articles after neoadjuvant chemoradiotherapy is shown in Table 3. The long-term outcomes are shown in Table 4. The long-term outcomes included local recurrence, distant metastasis, cancer-related death, disease-free survival, and overall survival (Fig. 1).

Quality assessment

We evaluated the quality of the included studies using the NOS assessment scale (Newcastle-Ottawa Quality Assessment Scale). The score indicated three levels of quality: low (1–3), moderate (4–6), and high (7–9). We included 11 studies in our study (4 RCNT and 7 prospective non-randomized controlled trial (PNCT)) with moderate to high quality. No relevant RCTs were found during the database search. The details are shown in Table 1.

Juuy	Year Co	Country	Case	0		Age			Quality	Quality control		Diagnostic criteria	Study design	Neoadjuvant therapy	Evaluation Follow-up time (mon	Follov time	Follow-up time (month)	th)	Radical surgery type	NOS score
			WS	RS	Ш	WS	RS	Ш	Selection	ion Comparability	Outcome				Time (week)	WS	RS	LE A	APR or LAR	
Ayloor [16]	2013 India	Idia	23	10	I.	50	55	I	m	2	-	023+ CT, ultrasound	RNCT	Long-range radiotherapy	4–6	72	72	< <	APR or LAR	9
Dalton [17]	2012 UK	¥	9	9	I	68	69	I	ŝ	2	2	1245	PNCT	Cape/4550.4Gy	6-8	25.3	39.3	F	TME	\sim
Habr [11]	2004	Brazil	71	22	I	58.1	53.6	I	2	£	-	123+CT	PNCT	5-FU+LV/45-50.4Gy	6-8	57.3	48	F	TME	9
Lai [18]	2016 Ta	Taiwan	18	26	I	67.5	63.7	I	7	7	5	(146)	RNCT	5-FU/45-50.4Gy	8-12	49	42	1 7 C O Y	APR or LAR or LAR+ loop stoma	9
Lee [1 <mark>9</mark>]	2015 Ko	Korea	00	28	16	64	70	70	£	2	-	345	PNCT	50.4Gy	6-10	41	41	41 TI	TME	9
Li [20]	2015 Cł	China	30	92	I	62	56	T	£	F	2	12345	PNCT	Cape/50;25Gy	8-10	58	58	۲ ا	APR or LAR	9
Mass [21]	2011	Netherlands	21	20	I	65	99	T	£	2	2	12345	PNCT	Cape/45Gy	6–8	25	35	F I	TME	2
Renehan [22]	2016 UI	UK	129	109	I	66.9	65	I	7	m	2	12346	PNCT	5-FU/45Gy	œ	33	33	F I	TME	\sim
Smith [23]	2012 U	NSA	32	57	I	70	60	I	m	m		12345	PNCT	5-FU+ Cape/50.4Gy	4-10	28	43	I I		\sim
Yeom [24]	2019 Ko	Korea	15	129	25	74	64.8	73	2	m	2	12345	RNCT	Cape /50.4Gy or Capeox/ 50.4Gy or 5-FU /50.4Gy	Ø	60	60	60 TI	TME	\sim
Wang [25]	2020 Cł	China	59	179	I.	58	57	I	2	2	2	12345	RNCT	5-FU+ Cape/50.4Gy	6-12	60	60	F I	TME	9

Study	T stage ((n; %)					N stage (n	; %)				
				T3-T4			N0			N1-N2		
	WS	RS	LE	WS	RS	LE	WS	RS	LE	WS	RS	LE
Ayloor [16]	9	4	_	14	6	_	-	-	-	_	-	-
Dalton [17]	1	-	-	5	6	-	1	-	-	5	6	-
Habr [11]	14	1	-	57	21	-	55	16	-	16	6	-
Lai [18]	-	-	-	-	-	-	-	-	-	-	-	-
Lee [19]	5	6	7	3	22	9	5	13	14	3	15	2
Li [20]	8	24	-	22	68	-	14	39	-	16	53	-
Mass [21]	б	1	-	15	19	-	6	3	-	15	17	-
Renehan [22]	31	24	-	98	85	-	45	47	-	84	181	-
Smith [23]	10	11	-	22	39	-	14	20	-	18	31	-
Yeom [24]	3	8	2	12	121	23	5	75	19	10	54	6
Wang [25]	б	8	-	53	171	-	14	47	-	45	132	-
Total	93 (23.6)	87 (13.3)	9 (21.9)	301 (76.3)	558 (85.5)	32 (78.1)	159 (42.8)	260 (34.4)	33 (80.4)	212 (57.2)	495 (65.5)	8 (19.6)
Clinical stage (r	n; %)											
I			II			111				IV		
WS	RS	LE	WS	RS	LE	WS	RS	LE		WS	RS	LE
-	-	-	-	-	-	-	-	-		-	-	_
-	-	_	-	-	-	-	-	-		-	-	-
-	-	-	-	-	-	-	-	-		-	-	_
-	-	-	11	8		7	18	-		-	-	-
-	-	-	-	-	-	-	-	-		-	-	-
-	-	-	-	-	-	-	-	-		-	-	-
-	-	-	-	-	-	-	-	-		-	-	-
-	-	-	-	-	-	-	-			-	-	-
8	2	-	6	18	_	18	31	-		-	-	-
-	-	-	-	-	-	-	-	-		-	-	-
-	-	-	-	-	-	-	-	-		-	-	-
8 (16)	2 (2.5)	-	17 (34)	26 (33.7)	-	25 (50)	49 (63.8)	-		-	-	-

Table 2 T stage, N stage and clinical stage of the included articles

Primary objectives

WS group versus RS group

Local recurrence, distant metastasis, and cancer-related death

The WS group had a higher recurrence rate than the RS group. Other primary objectives were similar in the two groups. The details were as follows: 9 studies reported clinical data on local recurrence, and the WS group had a higher recurrence rate than the RS group in the fixed-effects model (OR 7.32, 95% CI 3.58 to 14.95, P < 0.001, chi² = 4.51, P = 0.81, $I^2 = 0\%$, Fig. 2a). Western studies (OR 7.22, 95% CI 1.36 to 38.37, P = 0.02, chi² = 2.03, P = 0.36, $I^2 = 1\%$, Fig. 2a), and Eastern studies (OR 5.57, 95% CI 2.36 to 13.15, P < 0.001, chi² = 0.69, P = 0.95, $I^2 = 0\%$, Fig. 2a) had the same results in local recurrence. The WS group had a similar distant metastasis rate as

the radical surgery group in the fixed-effects model with high heterogeneity (OR 1.03, 95% CI 0.59 to 1.81, P = 0.92, chi² = 13.01, P = 0.11, $I^2 = 38\%$, Fig. 2b). The occurrence of cancer-related death (OR 0.44, 95% CI 0.12 to 1.60, P = 0.22, chi² = 4.07, P = 0.25, $I^2 = 26\%$, Fig. 2c) was similar between the two groups in the fixed-effects model with little heterogeneity.

WS group versus LE group

Distant metastasis and local recurrence

The primary objectives were similar in the two groups. Similar distant metastasis rates were found in the two groups in the fixed-effects model with little heterogeneity (OR 1.24, 95% CI 0.33 to 4.69, P = 0.75, chi² = 0.94, P = 0.33, $I^2 = 0\%$, Fig. 3a). Two studies reported clinical data on local recurrence, which was similar in the two

Study	Pathologi	c T stage (<i>n</i> ;	%)								Pathologic	N stag	e (<i>n</i> ; %)	
	ypT0		ypT1		ypT2		ypT3		урТ	4	ypN0		ypN1-2	
	RS	LE	RS	LE	RS	LE	RS	LE	RS	LE	RS	LE	RS	LE
Ayloor [16]	6	-	-	-	3	-	1	-	-	-	6	-	5	-
Dalton [17]	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Habr [11]	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lai [18]	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lee [19]	13	6	2	6	9	4	4	0	0	0	24	-	4	-
Li [20]	-		-		-	-		-	-	-	-	-	-	-
Mass [21]	-		-		-	-		-	-	-	-	-	-	-
Renehan [22]	-		-		-	-		-	-	-	-	-	-	-
Smith [23]	-		-		-	-		-	-	-	-	-	-	-
Yeom [24]	46	12	47	11	-	-	36	2	-	-	108	-	21	-
Wang [25]	-		-		-	-		-	-	-	-	-	-	-
Total	65 (38.9)	18 (43.9)	49 (29.3)	17 (41.4)	12 (7.1)	4 (9.7)	41 (24.7)	2 (5)	0	0	138 (82.1)		30 (17.9)	-
Pathologic sub	otypes													
Well differentia	ated	Moderate	differentiate	ed		Poorly (differentiated	d				Unkr	nown	
WS	RS	WS		RS		WS			RS			WS	RS	
-	-	-		-		-			-			-	-	
-	-	-		-		-			-			-	-	
-	-	-		-		-			-			-	-	
-	-	-		-		-			-			-	-	
-	-	-		-		-			-			-	-	
-	-	-		-		-			-			-	-	
-	-	-		-		-			-			-	-	
5	15	86		104		2			14			36	95	
-	-	-		-		-			-			-	-	
-	-	-		-		-			-			-	-	
2	29	45		126		2			0			10	24	

Table 3 Pathologic staging and subtypes of included articles after radiotherapy

groups in the fixed-effects model (OR 1.46, 95% CI 0.49 to 4.35, P = 0.50, chi² = 1.69, P = 0.19, $I^2 = 41\%$, Fig. 3b).

Secondary objectives

WS group versus RS group

2-Year DFS, 2-year OS, 5-year DFS, and 5-year OS

The secondary objectives were similar in two groups. The details are as follows: seven studies with WS group had similar 2-year DFS as the RS group in the fixed-effects model with little heterogeneity (OR 0.77, 95% CI 0.46 to 1.28, P = 0.3, chi² = 9.44, P = 0.15, $I^2 = 36\%$, Fig. 4a). Seven studies that reported OS with WS groups had similar 2-year OS as the surgery group in the fixed-effects model with little heterogeneity (OR 0.75, 95% CI 0.40 to 1.41, P = 0.90, chi² = 8.44, P = 0.21, $I^2 = 29\%$, Fig. 4b). The 5-year DFS (OR 0.47, 95% CI 0.04 to 5.90, P = 0.56, chi² = 17.59, P < 0.001, $I^2 = 89\%$, Fig. 4c) and

5-year OS (OR 1.94, 95% CI 0.19 to 19.62, P = 0.56, chi² = 10.25, P = 0.02, $l^2 = 71\%$, Fig. 4d) were similar in both groups in the random-effects model.

Publication bias

To determine whether the article had publication bias, we used RevMan 5.0 software to test the index of distant metastasis rate of the included literature and obtained a funnel plot. The points were evenly distributed in the funnel plot, indicating no publication bias in the metaanalysis.

Discussion

Radical surgery of mid-low rectal cancer can bring great trauma to patients, and some patients require removal of their anus [27], which could result in a serious impact on patients' physical and mental health [28]. In 2004, Habr-Gama first reported the wait and see (non-

Study	LR (<i>n</i> /%)			DM (n/%)			CRD (<i>n</i> /%)				
	WS	RS	LE	WS	RS	LE	WS	RS	LE		
Ayloor [16]	7	0	-	3	2	-	-	_	-		
Dalton [17]	-	-	-	-	-	-	-	-	-		
Habr [11]	2	0	-	3	3	-	0	2	-		
Lai [18]	2	0	-	0	1	-	-	-	-		
Lee [19]	2	1	6	0	3	2	-	-	-		
Li [20]	2	2	-	1	5	-	0	4	-		
Mass [21]	1	0	-	0	1	-	-	-	-		
Renehan [22]	-	-	-	-	-	-	-	-	-		
Smith [23]	6	0	-	3	3	-	1	0	-		
Yeom [24]	6	15	5	4	5	4	-	-	-		
Wang [25]	7	1	-	6	17	-	-	-	-		
Total	35 (12.6)	19 (3.3)	11 (26.8)	20 (7.2)	40 (7.1)	6 (14.6)	1 (0.7)	6 (3.5)	-		
2-year OS (<i>n</i> /%)	2-year Df	=S (<i>n/</i> %)		5-year OS	(n/%)	5-year DFS	(n/%)			
WS	RS	LE	WS	RS	LE	WS	RS	LE	WS	RS	LE
-	-	-	-	-	-	-	-	-	-	-	-
6	6	-	6	6	-	-	-	-	-	-	-
71	20	-	70	19	-	71	20	-	68	19	-
18	26	-	-	-	-	18	24	-	-	-	-
-	-	-	6	25	10	-	-	-	-	-	-
30	92	-	29	91	-	30	88	-	27	85	-
21	19	-	19	19	-	-	-	-	-	-	-
107	100	-	100	89	-	-	-	-	-	-	-
31	57	-	28	56	-	-	-	-	-	-	-
-	-	-	-	-	-	3	128	-	3	110	-
-	_	-	-	-	-	53	175	-	-	-	-
284 (92.5)	320 (96.3)	-	258 (86.8)	305 (91.3)	10 (62.5)	175 (90.6)	435 (97.0)	_	98 (84.4)	214 (88.0)	-


Table 4 Characteristics of the included articles

Notes: LR local recurrence, DM distant metastasis, CRD cancer-related death, DFS disease-free survival, OS overall survival

surgical) treatment strategy for low rectal cancer patients who obtained cCR after chemoradiotherapy. A total of 71 patients who achieved a cCR status were only closely followed (wait and see) for an average of 57.3 months. Two patients had recurrence in the intestinal lumen, and 3 patients had distant metastasis. The 5-year DFS and OS rates were 92%, and 100% respectively. The other 194 patients without clinical complete response underwent radical surgery. A total of 22 patients had pathologically confirmed pCR (pathologically complete response). The 5-year disease-free survival rate and 5year overall survival rates were 83% and 88%, respectively. No significant differences were found between the two groups. After expanding the sample size, Habr-Gama got the same conclusion [29]. Subsequently, many studies about cCR have emerged, and they also confirmed the treatment effect of the wait and see strategy [30, 31]. Professor Lu found that 50% of cT1-2 tumors could disappear completely, and postoperative pathology was ypT0 [32]. In addition, as the tumor shrank, local excision surgery and the wait and see strategy were able to ensure organ preservation. Therefore, we aimed to include cCR patients and intended to compare the advantages and disadvantages of the three treatment methods.

Local recurrence, distant metastasis, and cancer-related death

In this meta-analysis, we found that the WS group had a higher local recurrence rate than the RS group. This result was similar to professor Li's research. Approximately 81.9% of patients were at the beginning T3–4 and 67.8% N1–2 (Table 2). A total of 19.4% of patients were ypT3–T4 and 11.8% of patients were ypN1–2. Patients in whom T stage and N stage were not obviously reduced were prone to relapse after neoadjuvant therapy. Patients could relapse in the WS group easily. However,



in the RS surgery group, the recurrence rate was reduced to below 10%. Because few patients had incomplete information in LE group, no significant difference in local recurrence rate was seen in the WS and LE group. We speculated that some patients achieved cCR status in the WS group, but the tumor was not completely cured, so the recurrence rate would increase. But in the surgery group, the tumor has been removed and the recurrence rate can be appropriately reduced. Approximately 7.2% of patients had distant metastasis in the WS group and 7.1% of patients had distant metastasis in the RS group. Fewer studies involved the CRD indicator. There were no significant differences of distant metastasis rate and CRD in three groups. Dossa and Li also arrived at the same result. The wait and see strategy had some advantages, such as reducing surgical trauma, improving the quality of life, and no raising distant metastasis rate.


DFS and OS


The 2-year DFS rate was 86.8% and 91.3% in the WS and RS groups, respectively. The 2-year OS rates were 92.5% and 96.3% in the WS and RS groups, respectively. The WS group had similar 2-year DFS and OS and 5-year DFS and OS as the RS group. Patients with cCR status were sensitive to neoadjuvant therapy and had good biological behavior, so patients' survival was good in all groups. Due to the huge difference in the baseline data, we deleted Lin's study [33]. We obtained similar results as Li's research and Dossa's research. Lin's study caused big bias and led to the false result. Arauio and Simth's research included patients with tumor stage IV, so we

abandon them [34, 35]. Currently, doctors use highsensitivity MRI and colonoscopy to find small tumor lesion and deal with them in time [36, 37]. The included articles had salvage therapy for patients with local recurrence, which included chemotherapy and surgical treatment. The patients of the WS group, who had not experienced large surgical trauma, had better immunity than surgical group, and they could endure the subsequent treatments.

The specific plan and efficacy of NRCT

The details of the neoadjuvant treatment are shown in additional file 5. The NCRT of Li's research (50 Gy/25 f/ 2 Gy, capecitabine, 825 mg/m2 bid, concurrently) had the best clinical effect. This research had the biggest PCR rate and the best DFS/OS rate with long-term radiotherapy and capecitabine. Professor Harb also conducted long-term radiotherapy + 5-fluoracil for neoadjuvant therapy, with a PCR rate of approximately 8.3%. Due to the improvement in the level of radiotherapy and the use of capecitabine sensitizers, the PCR rate was about 20%. At present, the standard neoadjuvant treatment is radiotherapy (45 to 50.4 Gy/25 to 28 f) and capecitabine at 825 mg/m^2 , twice per day (total dose of 1 $650 \text{ mg/m}^2/\text{d}$). Surgery should be approximately about 6-8 weeks and 12 weeks at the maximum. In this way, the tumor can shrink to a minimum and the edema of the irradiation field completely disappeared, improving the PCR and anus preservation rate [38]. The included literature had a long time span, and the neoadjuvant treatment plan was not uniform, which could affect the





final result. With the further standardization of neoadjuvant treatment, we hoped more and more studies with the uniform adjuvant treatment plans would appear.

Previous meta-analysis and our update

Although Professor Dossa included 23 studies in his research, only 15 studies had control groups and 5 studies had specific data of comparison between two groups. He proposed that there were no significant differences in non-regrowth recurrence, cancer-specific mortality, overall survival, and disease-free survival. There were 9 studies in Professor Li's research, and he reported that two patient groups were similar in distant metastasis rates, disease-free, and overall survival, but the nonsurgical group had a higher risk of 1-, 2-, 3-, and 5-year local recurrence. Our report also showed a higher local recurrence rate in the WS group than the RS group, which affirmed the effect of wait and see strategy for patients with cCR status. Subgroup analysis of Eastern and Western studies were also performed, and we hoped that more studies about cCR-related research of the WS group versus radical surgery or local excision would appear [39].

Arauio and Smith had patients with Stage IV; thus, we removed those two studies. More cases with T3–4 and N1–2 stage are more needed to perform neoadjuvant treatment than T1–2 and N0 stage. We found that some patients with T3–4 and N1–2 stage could obtain cCR after neoadjuvant treatment with better prognosis than adjuvant treatment. Sometimes, T1–2 and N0 stage might be treated directly with surgery and obtained a considerable effect. However, the relevant prognosis of

patients with T and N stage were not specified in the article, and we could not use the meta-analysis to define the specific meaning of T and N stage for cCR. Most patients had achieved T and N stage reduction after neoad-juvant therapy, but there was too little available information to form a conclusion about a specific treatment method for these patients.

Limitations

This study might have several limitations. First, 11 studies (4 RCNT and 7 PNCT) with a total of 1131 patients could not represent the highest level of evidence due to the non-included RCTs. Second, incomplete clinical data and some unbalanced baseline characteristics could affect the results. Third, differences between Eastern and Western population groups could cause potential selection bias. Finally, more cCR patients need to be included. Furthermore, more RCTs for the wait and see strategy versus surgery for cCR are necessary.

Conclusion

In summary, this study compared the reliability and safety of the wait and see strategy to radical surgery and local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy. The WS group had higher local recurrence rate than the RS group. There was no significant difference in other data. With neoadjuvant chemoradiotherapy development and appropriate salvage therapy for local recurrence, the wait and see strategy could minimize surgical trauma and preserve the anus and had the advantages for cCR patient.

2.2. We set in Databa 2010 70 71 19 22 1.2% 11.05 [0.2, 105.52] Hab 2004 70 71 19 22 1.2% 11.05 [0.9, 112.9] Mass 2011 19 22 19 19 20 5.5% 0.55 [0.12, 105.52] Mass 2011 19 22 229 198 109 64.5% 0.77 [0.41, 1.47] Transit 2012 0.72 23 25 57 15.5% 0.13 [0.04, 1.29] Mass 2011 20 22 229 18 7.3% 0.35 [0.05, 2.66] Le 2015 0.6 8 25 28 8.3% 0.36 [0.05, 2.66] Le 2015 0.6 8 25 29 30 91 92 4.4% 0.32 [0.02, 1.76] Heterogenety, Chi ² = 0.00, 1 ² P = 0.40, 1 ² D = 0.5% Test for overall effect Z = 0.59 (P = 0.49) Z.2 castern Lee 2015 6 6 8 25 29 3.04 Heterogenety, Chi ² = 0.01 (P = 0.40, 1 ² D = 0.5%) Test for overall effect Z = 1.26 (P = 0.5), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.26% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 1.26 (P = 0.15), 1 ² D = 0.5% Test for overall effect Z = 0.279 Total effect Z = 0.370 Total effect Z = 0.37 (D = 0.30) Z.12 eastern Lia 2016 19 18 18 25 26 2.4% 2.18 [0.08, 56.48] Lia 2016 19 18 18 25 26 2.4% 2.18 [0.08, 56.48] Lia 2016 19 18 18 25 26 2.4% 2.18 [0.08, 56.48] Lia 2016 19 18 18 25 26 2.4% 2.18 [0.08, 56.48] Total events 2.35 (P = 0.10), 1 ² D = 0.5% Test for overall effect Z = 0.37 (P = 0.30) Z.12 eastern Lia 2016 19 18 18 25 26 2.4% 2.18 [0.08, 56.48] Lia 2016 19 18 10 23 30 01 19 2.22% 30 A A B A D A D A D A D A D A D A D A D A	a Study or Subgroup	WS Events	Total	surg Events		Weight	Odds Ratio M-H, Fixed, 95% Cl	Odds Ratio M-H, Fixed, 95% Cl	
Hat 2004 70 71 19 22 1.2% 11.0 5 [1.0.5] 12.39 Mass 2011 19 21 19 22 2 2.2% 1.0 5 [5.06, 5.12.9] Prenehan 2016 100 129 89 100 64.5% 0.77 [0.41, 1.47] Sinth 2012 28 23 65 57 15.0% 0.13 [0.01, 1.7] Subtract (6% C) 2.29 214 87.3% 0.38 [0.05, 2.68] Les 2015 6 6 0 25 28 8.3% 0.38 [0.05, 2.68] Les 2015 6 6 0 25 28 8.3% 0.38 [0.05, 2.68] Les 2015 6 0 0 10 1 (P = 0.49); P = 0.% Test for overall effect Z = 0.80 (P = 0.49) 2.2.2 cestern Les 2015 6 6 0 25 28 8.3% 0.38 [0.05, 2.68] Ladvida (6% C) 287 334 100.0% 0.77 [0.46, 1.28] Heterogeneth: Ch ⁺ = 0.43, dF = 6 (P = 0.15); P = 0.% Test for overall effect Z = 1.28 (P = 0.49) 2.1.4 vests Test for overall effect Z = 1.28 (P = 0.49); P = 0.% Test for overall effect Z = 1.28 (P = 0.49); P = 0.% Test for overall effect Z = 1.28 (P = 0.49); P = 0.% Test for overall effect Z = 1.28 (P = 0.49); P = 0.% Test for overall effect Z = 1.28 (P = 0.49); P = 0.% Test for overall effect Z = 1.02 (P = 0.15); P = 0.% Test for overall effect Z = 1.02 (P = 0.31) Total events 250 304 Heterogeneth; Ch ⁺ = 0.43, dF = 6 (P = 0.15); P = 0.% Test for overall effect Z = 1.04 (P = 0.39); P = 0.% Test for overall effect Z = 1.04 (P = 0.30) 2.1.4 vests Test for overall effect Z = 1.04 (P = 0.30) 2.1.4 vests Test for overall effect Z = 1.04 (P = 0.30) 2.1.2 2.2 2.2 2.2 2.2 2.2 1.4 81.38 0.04 (0.19, 1.00] Simutotical (9% C) 2.2 2.2 2.2 2.2 1.4 81.38 0.04 (0.19, 1.00] Simutotical (9% C) 2.3 30 91 92 2.2 0.5 3.37 1.000.04 2.5 2.0] Simutotical (9% C) 307 332 100.05 0.75 [0.40, 1.41] Total events 48 116 Heterogeneth; Ch ⁺ = 8.44, dF = 6 (P = 0.21); P = 2.9% Test for overall effect Z = 0.30 (P = 0.37) Total events 48 116 Heterogeneth; Ch ⁺ = 8.44, dF = 6 (P = 0.21); P = 2.9% Test for overall effect Z = 0.30 (P = 0.37) Total events 48 116 Heterogeneth; Ch ⁺ = 8.44, dF = 6 (P = 0.21); P = 2.9% Test for overall effect Z = 0.59 (P = 0.50) Total events 48 116 Heterogeneth; Ch ⁺ = 8.44, dF = 6 (P = 0.21); P = 2.9% Test for overall effect Z = 0.59 (P = 0.50) Total	2.2.1 western								
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Dalton2012	6	6	5	6	1.2%	3.55 [0.12, 105.82]		
$\begin{aligned} & \text{Renchan 2016} & 100 & 129 & 89 & 100 & 64.5\% & 0.77 [0.41, 1.47] \\ & \text{Subtratel (65K C)} & 259 & 214 & 87.3\% & 0.33 [0.48, 1.42] \\ & \text{Subtratel (65K C)} & 259 & 214 & 87.3\% & 0.33 [0.48, 1.42] \\ & \text{Test for overall effect Z = 0.69 (P = 0.49)} \\ & \text{Z-Z eastern} \\ & \text{Les 2015} & 6 & 8 & 2.5 & 28 & 8.3\% & 0.36 [0.05, 2.66] \\ & \text{L2015} & 6 & 8 & 2.5 & 28 & 8.3\% & 0.36 [0.05, 2.66] \\ & \text{L2016} & 5 & 9 & 9 & 0.49, P = 0.49 \\ & \text{Z-Z eastern} \\ & \text{Les 2015} & 6 & 8 & 2.5 & 28 & 8.3\% & 0.36 [0.05, 2.66] \\ & \text{L2016} & 5 & 9 & 9 & 0.49, P = 0.94, P = 0.$	Harb 2004	70	71	19	22	1.2%	11.05 [1.09, 112.39]		
Similar 2012 28 32 56 67 15.0% 0.13 $[0.01, 1.17]$ Total events 223 188 Heterogeneity: Ch ⁺ = 8.4, <i>df</i> = 4 (ℓ = 0.08; ℓ = 5.3% Test for overall effect Z = 0.69 (ℓ = 0.49) 2.2.2 eastern Lie 2015 6 8 25 28 8.3% 0.36 $[0.05, 2.66]$ Li 2015 28 30 91 92 4.4% 0.32 $[0.02, 5.26]$ Subtotal (6% C) 38 1120 12.7% 0.36 $[0.07, 1.76]$ Total events 35 Test for overall effect Z = 1.28 (ℓ = 0.20); ℓ = 0.98 Heterogeneity: Ch ⁺ = 8.4, <i>df</i> = 6 (ℓ = 0.15; ℓ = 36% Test for overall effect Z = 1.02 (ℓ = 0.31) Favours experimental Favours control Subtotal (6% C) 259 27 334 100.0% Total (9% C) 259 274 94.3% 0.36 $[10.02, 5.26]$ Odds Ratio Odds Ratio C Moreal effect Z = 1.02 (ℓ = 0.31) Favours experimental Favours control Favours experimental Favours control Favour								•	
Subtrate (6% C) 259 214 97.3% 0.33 (0.48, 1.42) Total events 223 188 Heterogeneity: Chi ⁺ = 2.4.4, df = 4 ($P = 0.08$); $P = 53\%$ Test for overall effect Z = 0.68 ($P = 0.49$) 2.2.2 eastern Le 2015 6 8 2.5 28 8.3% 0.36 (0.05, 2.66) Li 2015 29 30 91 92 4.4% 0.35 (0.07, 1.76) Total events 000, df = ($P = 0.94$); $P = 0\%$ Test for overall effect Z = 1.2 ($P = 0.94$); $P = 0\%$ Test for overall effect Z = 1.2 ($P = 0.20$) Total events Total Z = 0.00, df = 1 ($P = 0.94$); $P = 0\%$ Test for overall effect Z = 1.2 ($P = 0.20$) Total events Total Z = 0.13); $P = 33\%$ Test for overall effect Z = 1.2 ($P = 0.30$) Total events Total Z = 0.13; $P = 33\%$ Test for overall effect Z = 1.2 ($P = 0.30$) Total events Total Z = 0.10; $P = 33\%$ Test for overall effect Z = 1.2 ($P = 0.30$) Total events Total Z = 0.13; $P = 33\%$ Test for overall effect Z = 1.02; $P = 0.31$) Total events Total Z = 0.13; $P = 33\%$ Test for overall effect Z = 0.10; $P = 0.33$; $P = 33\%$ Test for overall effect Z = 0.10; $P = 0.30$; $P = 0.33$							•		
Total events 223 198 Heterogeneity: Ch ⁺ = 844, df = 6 = 0.08; l ⁺ = 53%. Test for overall effect Z = 0.69 (P = 0.49) 2.2.2 eastern Lee 2015 6 8 25 28 8.3% 0.36 [0.05, 2.66] Li 2015 29 30 91 92 4.4% 0.32 [0.02, 5.26] Subtotal (95% C) 297 334 100.0% 0.77 [0.46, 1.28] Total events 258 304 Heterogeneity: Ch ⁺ = 0.43, df = 6 (P = 0.91); l ⁺ = 36%. Test for overall effect Z = 1.28 (P = 0.20) Total events 42, df = 6 (P = 0.15); l ⁻ = 36%. Test for overall effect Z = 1.02 (P = 0.31) b undy of Subtotal (95% C) 297 334 100.0% 0.77 [0.46, 1.28] Odds Ratio MLF Keed, 95% Cl 0.01 01 100 Favours experimental Favours control b undy of Subtotal (95% C) 297 334 100.0% 0.77 [0.46, 1.28] Cl 1 west for overall effect Z = 1.02 (P = 0.31) b undy of Subtotal (95% C) 298 314 44 (10.80, 377.86] Heterogeneity: Ch ⁺ = 2.43, df = 6 (P = 0.17); l ⁺ = 36%. Total events 238 2011 21 21 19 20 2.0% 3.31 (0.13, 66.06] Subtotal (95% C) 259 214 94.3% 0.18 [0.01, 4.62] Subtotal (95% C) 259 201 Heterogeneity: Ch ⁺ = 2.43, df = 6 (P = 0.10); l ⁺ = 49%. Test for overall effect Z = 1.04 (P = 0.30) 2.12 eastern Lai 2015 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 18 18 25 22 3.2% 1.00 [0.04, 25.20] Subtotal (95% C) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: Ch ⁺ = 2.43, df = 6 (P = 0.72); l ⁺ = 29%. Test for overall effect Z = 0.35 (P = 0.73) Total events 284 317 Heterogeneity: Ch ⁺ = 2.43, df = 6 (P = 0.27); l ⁺ = 29%. Test for overall effect Z = 0.36 (P = 0.37) c dots Ratio d ML Random, 95% Cl ML Ra		28		56					
Heterogeneity: Ch ² = 0.44, df = 4 ($p = 0.08$); $p = 53\%$ Test for overall effect Z = 0.69 ($p = 0.49$) 2.22 easem Le 2015 6 8 25 28 0.3% 0.36 [0.05, 2.66] Li 2015 29 30 91 22 4.4% 0.32 [0.02, 5.26] Subtoral (6% C) 38 120 12.7% 0.35 [0.07, 1.76] Total events 35 116 Heterogeneity: Ch ² = 0.00, df = ($p = 0.49$), $p = 0\%$ Test for overall effect Z = 1.28 ($p = 0.20$) Total events 226 3 004 Heterogeneity: Ch ² = 0.00, df = ($p = 0.49$), $p = 0\%$ Test for overall effect Z = 1.02 ($p = 0.30$) Total events Total Events Total Weinth MH, Excel .55 (C) H.H. Fixed .95% CI H.H. Fixed .95% CI			259		214	87.3%	0.83 [0.48, 1.42]	-	
Test for overall effect $Z = 0.69$ (P = 0.49) 2.2. easien Lee 2015 6 8 25 28 8.3% 0.36 [0.05, 2.66] Li 2015 29 30 91 92 4.4% 0.32 [0.02, 5.26] Subtotal (6%; C) 38 120 12.7% 0.35 [0.07, 1.76] Total events 258 304 Heterogeneity: Ch ² = 0.43, df = 6 (P = 0.5); P = 0% Test for overall effect Z = 1.02 (P = 0.20) Total events 2.58 304 Heterogeneity: Ch ² = 0.43, df = 6 (P = 0.5); P = 36% Test for overall effect Z = 1.02 (P = 0.31) Exercise 2.58 304 Heterogeneity: Ch ² = 0.43, df = 6 (P = 0.5); P = 36% Test for overall effect Z = 1.02 (P = 0.31) Exercise 2.58 304 Heterogeneity: Ch ² = 0.43, df = 6 (P = 0.50); P = 36% Test for overall effect Z = 1.02 (P = 0.31) Exercise 2.58 304 Heterogeneity: Ch ² = 0.44, df = 6 (P = 0.50); P = 36% Test for overall effect Z = 1.04 (P = 0.30) 2.1.1 western Total events 2.26 2.09 % 1.74 (10.80, 377.86) Heterogeneity: Ch ² = 0.44, df = 6 (P = 0.10); P = 49% Test for overall effect Z = 1.04 (P = 0.30) 2.1.2 eastern Lia 2016 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 30 30 91 92 32.2% 1.00 (0.04, 25.20] Subtotal (6%; C) 307 332 100.0% 0.75 [0.40, 1.41] Total events 244 317 Heterogeneity: Ch ² = 0.14, df = 1.0P = 0.73) Favours experimental Favours control Exter overall effect Z = 0.35 (P = 0.73) Total (9%; C) 16 27 30 86 92 33.7% 0.74 (0.18, 30.77) Favours experimental Favours control Exter overall effect Z = 0.39 (P = 0.37) Favours experimental Favours control Exter overall effect Z = 0.39 (P = 0.37) Favours experimental Favours control Exter overall effect Z = 0.39 (P = 0.37) Favours experimental Favours control Exter overall effect Z = 0.39 (P = 0.37) Favours experimental Favours control Favours experi									
Lee 2015 6 8 25 28 8.3% 0.36 [0.05, 2.66] L2015 29 30 91 92 4.4% 0.37 [0.05, 2.66] Subtrate (6% C) 38 120 12.7% 0.35 [0.07, 1.76] Total events 35 116 Heterogeneity: Ch ² = 0.00, df = 1 ($P = 0.94$); $P = 0\%$ Testfor overall effect Z = 1.28 ($P = 0.30$) Total events 258 304 Heterogeneity: Ch ² = 0.43, df = 6 ($P = 0.15$); $P = 3\%$ Testfor overall effect Z = 1.02 ($P = 0.31$) b WS surg Odds Ratio b WS surg Odds Ratio b WS to the second					53%				
Li 2015 29 30 91 92 4.4% 0.32 [0.02, 5.26] Subtrata (95% Ch) 38 120 12.7% 0.35 [0.07, 1.76] Total events 25 116 Heterogeneity: ChP = 0.0, (-1 $P = 0.94$), P = 0% Test for overall effect $Z = 1.28 (P = 0.20)$ Total events 268 304 Heterogeneity: ChP = 0.43, df = 6 (P = 0.15), P = 36% Test for overall effect $Z = 1.02 (P = 0.31)$ Subtrat (95% Ch) 297 334 100.0% 0.77 [0.46, 1.28] Total events 268 304 Heterogeneity: ChP = 0.43, df = 6 (P = 0.15), P = 36% Test for overall effect $Z = 1.02 (P = 0.31)$ Subtrat (95% Ch) 209 9.31 120 120 20.0% 3.35 [0.12, 105.82] Harb 2004 71 71 120 222 0.9% 17.44 [0.80, 977.86] Mass 2011 21 121 19 20 2.0% 3.31 [0.13, 66.0] Subtrat (95% Ch) 259 244 94.3% 0.74 [0.18, 0.77, 68] Mass 2011 21 121 19 20 2.0% 3.31 [0.13, 66.0] Subtrat (95% Ch) 259 244 94.3% 0.70 [0.36, 1.36] Ordel events 7.36 201 Heterogeneity: ChP = 7.87, df = 4 (P = 0.10), P = 49% Test for overall effect $Z = 1.04 (P = 0.30)$ 2.12 eastern Lai 2016 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 30 30 91 92 3.2% 1.00 [0.04, 25.20] Subtrat (95% Ch) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: ChP = 7.43, (F = 6 (P = 0.27); P = 29% Test for overall effect $Z = 0.30$ (P = 0.37) Total events 284 317 Heterogeneity: ChP = 8.44, 68 (P = 0.17); P = 29% Test for overall effect $Z = 0.30$ (P = 0.37) Total events 198 214 Heterogeneity: ChP = 8.44, 68 (P = 0.27); P = 29% Test for overall effect $Z = 0.50$ (P = 0.50) Total events 17 29 30 65 92 33.7% 0.74 [0.14, 307, 746] Hab 2004 68 71 19 22 22.25% 7.74 (1.08, 307, 95% Cl) Hab 2004 68 71 19 22 22.25% 7.74 (1.08, 307, 95% Cl) Hab 2004 68 71 19 22 22.25% 7.74 (1.08, 307, 95% Cl) Hab 2004 68 71 19 22 22.25% 7.74 (1.08, 307, 95% Cl) Hab 2004 68 71 19 71 20 22 22.25% 7.74 (1.08, 307, 95% Cl) Hab 2004 68 71 19 72 202 22.5% 7.74 (1.08, 307, 95% Cl) Hab 2004 68 71 19 72 202 22.5% 7.74 (1.08, 307, 95% Cl) Hab 2004 68 71 19 72 202 22.5% 7.74 (1.09, 307, 756] Hab 2004 68 71 19 72 300 73 32 91 00.00% 1.94 (1.01, 10, 100 766 726 700 766									
Subtoral (95% C) 38 120 12.7% 0.35 (0.07, 1.76) Total events 35 116 Heterogeneity, Chi ² = 0.00, df = 1 (<i>P</i> = 0.94), <i>P</i> = 0% Test for overall effect Z = 1.28 (<i>P</i> = 0.20) Total events 258 304 Heterogeneity, Chi ² = 0.43 (<i>F</i> = 0/P = 0.5), <i>P</i> = 36% Test for overall effect Z = 1.02 (<i>P</i> = 0.31) b Surg Odds Ratio Odds Ratio Od									
Total events $35 = 116$ Heterogeneity: Ch ² = 0.43, df = 0/P = 0.49, P = 0% Test for overall effect $Z = 1.28$ ($P = 0.20$) Total events $258 = 30.44$ Heterogeneity: Ch ² = 0.43, df = 6 ($P = 0.15$); P = 36% Test for overall effect $Z = 1.02$ ($P = 0.31$) Stuty or Subgroup Events Total Events Total Weight M.H. Fixed, 95% CI Heterogeneity: Ch ² = 0.43, df = 6 ($P = 0.15$); P = 36% Test for overall effect $Z = 1.02$ ($P = 0.31$) Subtotal (95% CI) 297 Odds Ratio Odds Ratio MH.Random .95% CI Heterogeneity: Ch ² = 244, df = 6 ($P = 0.73$); P = 29% Total events 170 Odds Ratio MH.Random .95% CI Heterogeneity: Ch ² = 244, df = 6 ($P = 0.73$); P = 29%; P = 20, 20; P = 0.50;		29		91					
Heterogeneity: Ch ² = 0.00, df = 1 ($P = 0.34$); $P = 0\%$ Test for overall effect $Z = 1.28$ ($P = 0.20$) Total (95% C) 297 334 100.0% 0.77 [0.46, 1.28] Test for overall effect $Z = 1.02$ ($P = 0.5$); $P = 36\%$ Test for overall effect $Z = 1.02$ ($P = 0.5$); $P = 36\%$ Test for overall effect $Z = 1.02$ ($P = 0.5$); $P = 36\%$ Test for overall effect $Z = 1.02$ ($P = 0.5$); $P = 36\%$ Test for overall effect $Z = 1.02$ ($P = 0.5$); $P = 36\%$ Test for overall effect $Z = 1.02$ ($P = 0.5$); $P = 36\%$ Test for overall effect $Z = 1.02$ ($P = 0.5$); $P = 36\%$ Total (95% C) 220 9% CI MH, Fixed, 95% CI MH, Fixed, 95\% CI MH, Fixed, 95\% CI MH, Fixed		25	38	110	120	12.7%	0.35 [0.07, 1.76]		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Heterogeneity: Chi ² =	= 0.00, df = 1		0.94); l² =	0%				
Total events Total events T	l est for overall effect	t:∠=1.28 (F	r = 0.20	J)					
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			297		334	100.0%	0.77 [0.46, 1.28]	•	
Test for overall effect $Z = 1.02$ ($P = 0.31$) b UUT ULT THE Favours experimental Favours control Study or Subgroup Events Total Events Total Weight M-H. Fixed, 95% Cl 21.1 western Dation 2012 6 6 5 6 1.7% 3.55 [0.12, 10.5.82] Harb 2004 71 71 20 22 0.2% 3.31 [0.13, 86.08] Renehan 2016 107 129 100 109 81.3% 0.44 [0.19, 1.00] Study of Sci UL 259 214 94.3% 0.70 [0.36, 1.36] Heterogeneity: Ch ² = 7.87, df = 4 (P = 0.10); P = 49% Test for overall effect Z = 1.04 (P = 0.00); P = 49% Test for overall effect Z = 0.90 (P = 0.30) 2.1.2 eastern Lai 2016 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 30 30 91 92 3.2% 1.00 [0.4, 25.20] Total events 48 116 Heterogeneity: Ch ² = 0.4, df = 6 (P = 0.73); P = 0% Test for overall effect Z = 0.90 (P = 0.37) Total (95% Cl) 307 332 100.0% 0.75 [0.40, 1.41] Total (95% CL) 307 332 100.0% 0.75 [0.40, 1.41] Total events 48 116 Heterogeneity: Ch ² = 0.4, df = 6 (P = 0.21); P = 29% Test for overall effect Z = 0.90 (P = 0.37) Total (95% CL) 116 2.23, 3% 3.58 [0.67, 19.19] C WS SULUX Constrained Total Events Total Weight MH. Random, 95% Cl Harb 2004 68 71 19 22 32.3% 0.74 [0.48, 3.07] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total (95% CL) 116 2.43 100.0% 0.47 [0.04, 5.90] Total events 9 8 214 Heterogeneity: Ch ² = 1.4, dt, Ch ² = 1.75.9, dt = 2 (P = 0.0002); P = 89% Test for overall effect Z = 0.59 (P = 0.50) Study or Subgroup Events Total Events Total Weight MH. Random, 95% Cl Harb 2004 71 71 71 20 22 22.2% 1.744 [0.60, 377.86] Study or Subgroup Events Total Events Total Weight MH. Random, 95% Cl Harb 2004 71 71 71 20 22 22.2% 1.744 [0.60, 377.86] Harb 2004 71 71 71 20 22 22.2% 1.744 [0.60, 377.86] Harb 2004 71 71 71 20 22 22.2% 1.744 [0.60, 377.86] Harb 2004 71 71 71 20 307 Heterogeneity: Tau ² = 4.43; Ch ² = 1.75.9, dt = 2(P = 0.0002); P = 71% Total (95% CL) 778 319 100.0% 1.94 [0.19, 19.62] Harb 2004 71 71 71 20 72 22 22.2% 1.744 [0.60, 377.86] Harb 2004 68 60 P = 0.50			0		200				
Stuckor Subarroup Events Total Events Total Weight M.H. Fixed. 95% CI M.H. Fixed. 95% CI 21.1 western 0 6 6 5 6 1.7% 3.55 [0.12, 105.82] Hab 2004 71 71 20 22 0.9% 17.44 [0.80, 377.86] Mass 2011 21 21 19 20 20% 3.31 [0.13, 86.06] Simth 2012 31 32 57 57 8.3% 0.44 [0.19, 100] Stucktota (95% CI) 259 214 94.3% 0.70 [0.36, 1.36] 9 Stucktota (95% CI) 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2016 18 18 25 26 2.4% 2.18 [0.04, 56.48] Li 2016 18 18 25 26 2.4% 2.18 [0.04, 56.48] Li 2016 18 18 25 26 2.4% 2.18 [0.04, 1.41] Total events 284 317 Heterogeneity: ChP = 0.37)					36%		F		
Study or Subgroup Events Total Events Total Weight M.H. Exed, 95% CI M.H. Fixed, 95% CI	b						Odds Ratio	Odds Ratio	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Study or Subgroup	Events T	otal E	vents	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	
Harb 2004 Harb 2004 Total (95% Cl) Total (~		~	~	4 70/	2 66 10 42 405 001		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									
Simith 2012 31 32 57 57 8.3% 0.18 [0.01, 4.62] Subtotal (95% CI) 259 214 94.3% 0.70 [0.36, 1.36] Total events 236 201 Heterogeneity: Ch ² = 7.87, df = 4 (P = 0.10); P = 49% Test for overall effect Z = 1.04 (P = 0.30) 2.1.2 eastern Lai 2016 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 30 30 91 92 3.2% 1.00 [0.04, 25.20] Subtotal (95% CI) 48 118 5.7% 1.50 [0.15, 14.86] Total events 48 116 Heterogeneity: Ch ² = 8.44, df = 6 (P = 0.74); P = 0% Test for overall effect Z = 0.35 (P = 0.73) Total (95% CI) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: Ch ² = 8.44, df = 6 (P = 0.21); P = 29% Test for overall effect Z = 0.90 (P = 0.37) Subtotal (95% CI) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: Ch ² = 8.44, df = 6 (P = 0.21); P = 29% Test for overall effect Z = 0.90 (P = 0.37) Subtotal (95% CI) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: Ch ² = 8.44, df = 6 (P = 0.21); P = 29% Test for overall effect Z = 0.90 (P = 0.37) Subtotal (95% CI) 116 229 33.7% 0.74 [0.18, 3.07] Total events 98 214 Heterogeneity: Tau ² = 4.4; Ch ² = 1.75, gd f = 2 (P = 0.0002); P = 89% Test for overall effect Z = 0.59 (P = 0.50) Favours experimental Favours control Favours experimental Favours control Favours experimental Favours control C WS Subgroup Events Total Events Total Weight MH, Random, 95% CI Harb 2004 71 71 2 0 22 22.2% 17.44 (0.80, 377.86] Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Harb 2004 71 71 71 2 0 72 22.2% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Heterogeneity: Tau ² = 4.4; Ch ² = 10.25, df = 3 (P = 0.02); P = 71% Total (95% CI) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: Tau ² = 4.56 (P = 0.56) Cot 0.01 0.1 1 10 100 Favours experimental Favours control D 0.01 0.1 1 10 100 Favours experimental Favours control Harb 2004 71 77 12 307 Heterogeneity: Tau ² = 4.56 (P = 0.56) Cot 0.02 (0.50, 0.74] Harb 2									
Subtotal (95% CI) 259 214 94.3% 0.70 [0.36, 1.36] Total events 236 201 Heterogeneity: Ch ² = 7.87, df = 4 (P = 0.10); P = 49% Test for overall effect: Z = 1.04 (P = 0.30) 2.1.2 eastern Lai 2016 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 30 30 91 92 3.2% 1.00 [0.04, 25.20] Total events 48 116 Heterogeneity: Ch ² = 0.17 (df = 1 (P = 0.74); P = 0% Test for overall effect: Z = 0.35 (P = 0.74); P = 0% Test for overall effect: Z = 0.35 (P = 0.74); P = 0% Test for overall effect: Z = 0.00 (P = 0.71); P = 29% Test for overall effect: Z = 0.00 (P = 0.37) C VS Surg Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M.H.Random, 95% CI Harb 2004 68 71 19 22 32.3% 3.58 [0.67, 19.19] Li 2015 27 30 85 92 33.7% 0.74 [0.18, 3.07] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total effect: Z = 0.59 (P = 0.56) C WS Surg Odds Ratio Odds Ratio C U VS Surg Odds Ratio Odds Ratio C U Odd Ratio Odds Ratio C U Odds Ratio Odds Ratio Odds Ratio C U Odd Ratio Odds Ratio Odds Ratio C U Odd Ratio Odds Ratio Odds Ratio								·	
Total events 236 201 Heterogeneity: Ch ² = 7.87, df = 4 (P = 0.10); P = 49% Testfor overall effect Z = 1.04 (P = 0.30) 2.1.2 eastern Lai 2016 18 18 25 26 2.4% 2.18 [0.09, 56.48] Li 2015 30 30 91 92 3.2% 1.00 [0.04, 25.20] Subtotal (95% Cl) 48 118 5.7% 1.50 [0.15, 14.86] Total events 48 116 Heterogeneity: Ch ² = 0.35 (P = 0.73) Total (95% Cl) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: Ch ² = 8.44, df = 6 (P = 0.21); P = 29% Test for overall effect Z = 0.30 (P = 0.37) Total (95% Cl) 307 332 100.0% 0.75 [0.40, 1.41] Total events $P = 8.44$, df = 6 (P = 0.21); P = 29% Test for overall effect Z = 0.90 (P = 0.37) Total (95% Cl) 307 332 32 33.7% 0.74 [0.18, 3.07] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total (95% Cl) 116 243 100.0% 0.47 [0.04, 5.90] Total events 98 214 Heterogeneity: Tau ² = 4.31; Ch ² = 7.53, df = 2 (P = 0.0002); P = 89% Test for overall effect Z = 0.59 (P = 0.56) Cd Study or Subgroup Events Total Events Total Weight M.H. Random, 95% Cl Harb 2004 71 71 20 22 22.2% 17.44 (0.80, 377.86] Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total (95% Cl) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: Tau ² = 4.81; Ch ² = 17.52, df = 3 (P = 0.02); P = 71% Total (95% Cl) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: Tau ² = 4.65 (P = 0.56)				5,				◆	
Heterogeneity: Chi ^P = 7.87, df = 4 (P = 0.10); P = 49% Test for overall effect: $Z = 1.04$ (P = 0.30) 2.1.2 eastern Lai 2016 18 18 12 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 30 30 91 92 3.2% 1.00 [0.04, 25.20] Subtrotal (95% Cl) 48 118 5.7% 1.50 [0.15, 14.86] Total events 48 116 Heterogeneity: Chi ^P = 0.11, df = 1 (P = 0.74); P = 0% Test for overall effect: $Z = 0.35$ (P = 0.73) Total (95% Cl) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: Chi ^P = 8.4, df = 6 (P = 0.21); P = 29% Test for overall effect: $Z = 0.90$ (P = 0.37) Exoture subgroup Events Total Events Total Weight M-H. Random, 95% Cl Harb 2004 68 71 19 22 32.3% 3.58 [0.67, 19.19] Li 2015 27 30 85 92 33.7% 0.74 [0.18, 307] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total (95% Cl) 116 243 100.0% 0.47 [0.04, 5.90] Total events 98 214 Heterogeneity: Tau ^P = 4.43; Chi ^P = 1.759, df = 2 (P = 0.002); P = 89% Test for overall effect: $Z = 0.59$ (P = 0.56) Exoture subgroup Events Total Events Total Weight M-H. Random, 95% Cl Harb 2004 71 71 72 22 22.2% 3.78 (0.048 Ratio Odds Ratio Odds Ratio Events Total Events Total Weight M-H. Random, 95% Cl Harb 2004 71 71 71 20 22 22.2% 3.74 [0.18, 0.377, 86] Lai 2016 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total (95% Cl) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ^P = 10.25, df = 3 (P = 0.02); P = 71% Dot 1 0.1 1 10 100 Heterogeneity Tau ² = 3.81; Chi ^P = 10.25, df = 3 (P = 0.02); P = 71% Dot 1 0.1 1 10 100				201					
Lai 2016 18 18 25 26 2.4% 2.18 [0.08, 56.48] Li 2015 30 30 91 92 3.2% 1.00 [0.04, 25.20] Subtotal (95% CI) 48 118 5.7% 1.50 [0.15, 14.86] Total events 48 116 Heterogeneity: Chi ² = 0.11, df = 1 ($P = 0.74$); $P = 0\%$ Test for overall effect $Z = 0.35$ ($P = 0.73$) Total events 284 317 Heterogeneity: Chi ² = 4.4, df = 6 ($P = 0.21$); $P = 29\%$ Test for overall effect $Z = 0.90$ ($P = 0.37$) Total events 284 317 Heterogeneity: Chi ² = 4.4, df = 6 ($P = 0.21$); $P = 29\%$ Test for overall effect $Z = 0.90$ ($P = 0.37$) Total events Total Events Total Events Total Weight M.H. Random, 95% CI Harb 2004 68 71 19 22 32.3% 3.58 [0.67, 19.19] Li 2015 27 30 85 92 33.7% 0.74 [0.18, 3.07] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total events 98 214 Heterogeneity: Tau ² = 4.43; Chi ² = 17.59, df = 2 ($P = 0.0002$); $P = 89\%$ Test for overall effect $Z = 0.59$ ($P = 0.56$) Total events 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 19 30 30 88 92 22.9% 3.10 [0.16, 59.30] Total events 172 307 Heterogeneiby: Tau ² = 3.81; Chi ² = 0.50; P = 0.57) Total events 172 307 Heterogeneiby: Tau ² = 3.81; Chi ² = 0.50; P = 0.57)					49%				
Li 2015 30 30 91 92 3.2% 1.00 [0.04, 25.20] Subtotal (95% CI) 48 118 5.7% 1.50 [0.15, 14.86] Total events 48 116 Heterogeneity: Chi ^P = 0.11, df = 1 (P = 0.74); l ^P = 0% Test for overall effect: Z = 0.35 (P = 0.73) Total events 284 317 Heterogeneity: Chi ^P = 8.44, df = 6 (P = 0.21); l ^P = 29% Test for overall effect: Z = 0.90 (P = 0.37) Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Harb 2004 68 71 19 22 32.3% 3.58 [0.67, 19.19] Li 2015 27 30 85 92 33.7% 0.74 [0.18, 3.07] Yeam 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total (95% CI) 116 243 100.0% 0.47 [0.04, 5.90] Total events 8 8 214 Heterogeneity: Tau ² = 4.43; Chi ^P = 17.59, df = 2 (P = 0.0002); l ^P = 89% Test for overall effect: Z = 0.59 (P = 0.56) Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Harb 2004 71 71 20 22 22.2% 17.44 [0.80, 377.86] Lai 2016 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2015 19 30 88 92 22.9% 3.10 [0.16, 69.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ^P = 10.25, df = 3 (P = 0.02); l ^P = 71% Total events 172 30.6 (P = 0.57) Heterogeneity: Tau ² = 3.81; Chi ^P = 10.25, df = 3 (P = 0.02); l ^P = 71% Total events 172 - 0.56 (P = 0.57)									
Subtotal (95% Cl) 48 118 5.7% 1.50 [0.15, 14.86] Total events 48 116 Heterogeneity: Chi ^P = 0.11, df = 1 (P = 0.74); P = 0% Test for overall effect Z = 0.35 (P = 0.73) Total (95% Cl) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: Chi ^P = 8.44, df = 6 (P = 0.21); P = 29% 0.01 0.1 1 10 100 Fast for overall effect: Z = 0.90 (P = 0.37) Surg Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl Harb 2004 68 71 19 22 32.3% 3.58 [0.67, 19.19] 10 10 Li 2015 27 30 85 92 33.7% 0.74 [0.18, 3.07] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] 0.01 0.1 10 100 Total (95% Cl) 116 243 100.0% 0.47 [0.04, 5.90] 0.01 0.1 10 100									
Total events 48 116 Heterogeneity: $Chi^2 = 0.11$, $df = 1$ (P = 0.74); P = 0% Test for overall effect Z = 0.35 (P = 0.73) Total (95% CI) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: $Chi^2 = 8.44$, $df = 6$ (P = 0.21); P = 29% Test for overall effect Z = 0.90 (P = 0.37) Fevents Total Events Total Events Total Weight M.H.Random, 95% CI Harb 2004 68 71 19 22 32.3% 3.58 [0.67, 19.19] Li 2015 27 30 85 92 33.7% 0.74 [0.18, 3.07] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total (95% CI) 116 243 100.0% 0.47 [0.04, 5.90] Total events 98 214 Heterogeneity: $Tau^2 = 4.43$; $Chi^2 = 17.59$, $df = 2$ (P = 0.0002); P = 89% Test for overall effect Z = 0.59 (P = 0.56) Events Total Events Total Weight M.H.Random, 95% CI Harb 2004 71 71 71 20 22 22.2% 17.44 [0.80, 377.86] Li 2015 30 30 88 92 22.3% 3.78 [0.17, 83.46] Li 2015 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2015 18 18 18 24 26 22.1% 3.78 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total (95% CI) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: $Tau^2 = 3.81$; $Chi^2 = 10.25$, $df = 3$ (P = 0.02); P = 71% Total (95% CI) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: $Tau^2 = 3.81$; $Chi^2 = 10.25$, $df = 3$ (P = 0.02); P = 71% Total events 172 0.50 (P = 0.50)		30		91					
Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); P = 0% Test for overall effect: $Z = 0.35$ (P = 0.73) Total (95% CI) 307 332 100.0% 0.75 [0.40, 1.41] Total (95% CI) 307 332 100.0% 0.75 [0.40, 1.41] Total (95% CI) 307 332 100.0% 0.75 [0.40, 1.41] Total (95% CI) 307 Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Vents Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI Harb 2004 68 0.01 0.11 10 00ds Ratio Odds Ratio Odds Ratio Total (95% CI) 116 24 10 0.11 10 0.11 10 10 0.11 10 10 0.01 0.01 0 0		40	40	116	118	5.7%	1.30 [0.15, 14.86]		
Test for overall effect: $Z = 0.35$ (P = 0.73) Total (95% CI) 307 332 100.0% 0.75 [0.40, 1.41] Total events 284 317 Heterogeneity: Chi ² = 8.44, df = 6 (P = 0.21); I ² = 29% Test for overall effect: $Z = 0.90$ (P = 0.37) Events Total Events Total Events Total Weight M.H. Random, 95% CI Harb 2004 68 71 19 22 32.3% 3.58 [0.67, 19.19] Li 2015 27 30 85 92 33.7% 0.74 [0.18, 3.07] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total (95% CI) 116 243 100.0% 0.47 [0.04, 5.90] Total events 98 214 Heterogeneity: Tau ² = 4.43; Chi ² = 17.59, df = 2 (P = 0.0002); I ² = 89% Test for overall effect: $Z = 0.59$ (P = 0.56) C w/S surg Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M.H. Random, 95% CI Harb 2004 71 71 72 20 22 22.2% 17.44 [0.80, 377.86] Li 2015 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2016 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ² = 10.25, df = 3 (P = 0.02); I ² = 71% Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ² = 10.25, df = 3 (P = 0.02); I ² = 71% Total events 172 - 0.56 (P = 0.57)			(P = 0)		N96				
Total events 284 317 Heterogeneity: Chi ² = 8.44, df = 6 (P = 0.21); F = 29% 0.01 0.1 10 100 Test for overall effect: Z = 0.90 (P = 0.37) Surg Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl Harb 2004 68 71 19 22 32.3% 3.58 (0.67, 19.19) 0.01 0.1 10 100 Harb 2004 68 71 19 22 32.3% 0.74 (0.18, 3.07) 0.01 0.1 10 10 100 Yeom 2019 3 15 110 129 34.0% 0.04 (0.01, 0.17) 0.01 0.1 1 10 100 Total events 98 214 116 243 100.0% 0.47 [0.04, 5.90] 0.01 0.1 1 10 100 Total events 98 214 Heterogeneity: Tau" = 4.43; Chi ^P = 17.59, df = 2 (P = 0.0002); P = 89% Odds Ratio Odds Ratio M-H, Random, 95% Cl					0.70				
Heterogeneity: Chi ² = 8.44, df = 6 (P = 0.21); ² = 29% Test for overall effect: Z = 0.90 (P = 0.37) C WS Surg Odds Ratio Odds Ratio Study or Subgroup Events Total Weight M-H, Random, 95% CI Harb 2004 68 71 19 22 3.358 [0.67, 19.19] Harb 2004 68 71 19 22 3.358 [0.67, 19.19] Harb 2004 68 71 19 243 100.0% 0.44 [0.18, 3.07] Yeem 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total (95% CI) 116 243 100.0% 0.43 [0.04, 5.90] Favours control Cl WS Surg Odds Ratio Surg to dots Ratio <th col<="" td=""><td></td><td></td><td>307</td><td>o</td><td>332</td><td>100.0%</td><td>0.75 [0.40, 1.41]</td><td>•</td></th>	<td></td> <td></td> <td>307</td> <td>o</td> <td>332</td> <td>100.0%</td> <td>0.75 [0.40, 1.41]</td> <td>•</td>			307	o	332	100.0 %	0.75 [0.40, 1.41]	•
Unit of the constraint			(P - 0		200				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	- ,		•		29%		F		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	С	WS		surg			Odds Ratio	Odds Ratio	
Li 2015 27 30 85 92 33.7% 0.74 [0.18, 3.07] Yeom 2019 3 15 110 129 34.0% 0.04 [0.01, 0.17] Total (95% Cl) 116 243 100.0% 0.47 [0.04, 5.90] Total events 98 214 Heterogeneity: Tau ² = 4.43; Chi ² = 17.59, df = 2 (P = 0.0002); l ² = 89% Test for overall effect: $Z = 0.59$ (P = 0.56) $\frac{0}{100}$ WS Surg Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Harb 2004 71 71 20 22 22.2% 17.44 [0.80, 377.86] Lai 2016 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ² = 10.25; df = 3 (P = 0.02); l ² = 71% Test for overall affect $Z = 0.59$ (P = 0.57)	Study or Subgroup	Events 1	fotal I	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl	
Yeom 2019 3 15 110 129 34.0% 0.04 [$0.01, 0.17$] Total (95% Cl) 116 243 100.0% 0.47 [$0.04, 5.90$] Total events 98 214 Heterogeneity: Tau ² = 4.43; Chi ² = 17.59, df = 2 (P = 0.0002); I ² = 89% 0.01 0.1 100 Test for overall effect: Z = 0.59 (P = 0.56) Surg Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Harb 2004 71 71 20 22 22.2% 17.44 [0.80, 377.86] M-H, Random, 95% Cl Lai 2016 18 18 24 26 22.1% 3.78 [0.17, 83.46] Image: Chi and									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									
Total events 98 214 Heterogeneity: Tau ² = 4.43; Chi ² = 17.59, df = 2 (P = 0.0002); I ² = 89% 0.01 0.1 1 100 Test for overall effect: Z = 0.59 (P = 0.56) Surg Odds Ratio Odds Ratio Methods Surg Odds Ratio Odds Ratio Odds Ratio Mark Subgroup Events Total Events Total Weight M-H, Random, 95% CI Harb 2004 71 71 20 22 22.2% 17.44 [0.80, 377.86] M-H, Random, 95% CI Lai 2016 18 18 24 26 22.1% 3.78 [0.17, 83.46] M-H, Random, 95% CI Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] M-H, Random, 95% CI Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] M-H, Random, 95% CI Total (95% CI) 178 319 100.0% 1.94 [0.19, 19.62] M-H, Random, 95% CI M-H, Random, 95% CI Total events 172 307 M-H, Random, 95% CI M-H, Random, 95% CI M-H, Random, 95% CI		3		110					
Heterogeneity: Tau ² = 4.43; Chi ² = 17.59, df = 2 (P = 0.0002); P = 89% Interview of the second se			116		243	100.0%	0.47 [0.04, 5.90]		
Interrogeneity: Tau* 3.81; Chi* = 10.25, df = 3 (P = 0.02); P = 71% Interrogeneity: Tau* 3.81; Chi* = 10.25, df = 3 (P = 0.02); P = 71% Interrogeneity: Tau* 3.81; Chi* = 10.25, df = 3 (P = 0.02); P = 71% Interrogeneity: Tau* 3.81; Chi* = 10.25, df = 3 (P = 0.02); P = 71% Interrogeneity: Tau* 3.81; Chi* = 10.25, df = 3 (P = 0.02); P = 71% Interrogeneity: Tau* 3.81; Chi* = 10.25, df = 3 (P = 0.02); P = 71%			47.00		n - ^ ·	00000	0.007		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $					r = U.I	0002); I*=			
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl Harb 2004 71 71 20 22 22.2% 17.44 (0.80, 377.86) Image: Cl	-1								
Harb 2004 71 71 20 22 22.2% 17.44 [0.80, 377.86] Lai 2016 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total (95% Cl) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: Tau ^a = 3.81; Chi ^a = 10.25, df = 3 (P = 0.02); P = 71% 0.01 0.1 10 100	C Study or Subgroup		Intal I		Intal	Weight			
Lai 2016 18 18 24 26 22.1% 3.78 [0.17, 83.46] Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total (95% Cl) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ² = 10.25, df = 3 (P = 0.02); l ² = 71% Test for overall effect 7 = 0.66 (P = 0.57) 0.01 0.1 1 10 100									
Li 2015 30 30 88 92 22.9% 3.10 [0.16, 59.30] Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total (95% Cl) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ² = 10.25, df = 3 (P = 0.02); ² = 71% Test for everall effect 7 = 0.66 (P = 0.57) 0.01 0.1 1 10 100									
Wang 2020 53 59 175 179 32.8% 0.20 [0.05, 0.74] Total (95% Cl) 178 319 100.0% 1.94 [0.19, 19.62] Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ² = 10.25, df = 3 (P = 0.02); l ² = 71% 0.01 0.1 1 10 100									
Total events 172 307 Heterogeneity: Tau ² = 3.81; Chi ² = 10.25, df = 3 (P = 0.02); i ² = 71% 0.01 0.1 1 10 100									
Heterogeneity: Tau ² = 3.81; Chi ² = 10.25, df = 3 (P = 0.02); i ² = 71% 0.01 0.1 1 10 100			178		319	100.0%	1.94 [0.19, 19.62]		
Test for overall effect: 7 = 0.56 (P = 0.57) 0.01 0.1 1 10 100									
Example Example Formation Example Formation	Total events								

Therefore, we propose that the wait and see strategy could be a feasible model for cCR patient.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10. 1186/s12957-020-02003-6.

Additional file 2:. The details of diagnostic criteria of each method in each study.

Additional file 3:. The details of PICOS

Additional file 4:.

Additional file 1:.

Additional file 5:. The details of neoadjuvant treatment of studies

Additional file 6:. The details of Inclusion and Exclusion Criteria

Additional file 7:.

Additional file 8:.

Abbreviations

PNCT: Prospective non-randomized controlled trialRNCTRetrospective nonrandomized controlled trial5-FU5-FluorouracilCapeCapecitabineRSRadical surgeryTMETotal mesorectal excisionAPRAbdominal-perineal resectionLARLow anterior resectionClConfidence intervalOROdds ratiosOSOverall survivalSMDStandardized mean difference

Acknowledgments

We thank the Department of General surgery and Medical Imaging of the Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute for technical assistance.

Authors' contributions

All authors participated in the study. GHZ and DMY performed the literature search and the acquisition of data. LD and YY performed the data analysis. WHW and TY participated in the interpretation of data and revised the article for important intellectual content. All authors approved the final version of the article.

Funding

This work was supported by the Cancer Hospital of China Medical University. The funding project is the Science and Technology Department of Liaoning Province Fund from the Liaoning Province Natural Science Foundation of China (grant nos.2014225016).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no conflicts of interest.

Author details

¹Department of General surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No 44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, PR China. ²The Affiliated Hospital of Liaoning University of traditional Chinese Medicine, No 33 Beiling Street, Huanggu District, Shenyang 110042, Liaoning Province, PR China. ³Department of Medical Imaging, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No 44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, PR China.

Received: 15 April 2020 Accepted: 17 August 2020 Published online: 31 August 2020

References

- Sakamoto Y, Morohashi H, Yoshida E, et al. Treatment strategy for Stage IV rectal cancer. Gan To Kaqaku Ryoho. 2015;42:1313–515.
- Russell MM, Ganz PA, Lopa S, et al. Comparative effectiveness of sphinctersparing surgery versus abdominoperineal resection in rectal cancer: patientreported outcomes in National Surgical Adjuvant BrEast and Bowel Project Randomized Trial R-04. Ann Surg. 2015;261:144–8.
- Dumont F, Mariani A, D. Elias D, et al. Surgical strategy for low rectal cancers. J Visc Surg. 2015;152:739–44.
- Polanco PM, Mokdad AA, Zhu H, et al. Association of adjuvant chemotherapy with overall survival in patients with rectal cancer and pathologic complete response following neoadjuvant chemotherapy and resection. JAMA oncology. 2018;4:938–43.
- Galler AS, Petrelli NJ, Shakamuri SP. Rectal cancer surgery: a brief history. Surg Oncol. 2011;20(4):223–30.
- Corbellini C, Biffi R, Luca F, et al. Open, laparoscopic, and robotic surgery for rectal cancer: medium-term comparative outcomes from a multicenter study. Tumori. 2016;102(4):414–21.
- Cui Y, Yang X, Shi Z, et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2019;29: 1211–20.
- Perez RO, Habr-Gama A, São Julião GP, et al. Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: potential pitfalls of a multicentre observational study. Tech Coloproctol. 2018;22(2):141–2.
- Rombouts AJM, Hugen N, Elferink MAG, et al. Treatment interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients: a population-based study. Ann Surg Oncol. 2016;23(11):3593–601.
- Gérard JP, Chamorey E, Bourgade SG, et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 Randomized Trial. Radiother Oncol. 2015;115(2):246–52.
- Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7.
- Li J, Li L, Yang J, et al. Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Oncotarget. 2016;7:44857–70.
- Dossa F, Chesnev TR, Acuna SA, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenteol Hepatol. 2017;2:501–13.
- Zhang X, Xing DL, Zhou H, et al. Meta-analysis of safety of "Wait and See" strategy for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy. Chin J Gen Surg. 2018;27(10):1220–30.
- Buijo K, Rutkowski A. RE: Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108:djw291.
- Ayloor SR, Kondaveeti SS, Jayanand SB, et al. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided? Hepatogastroenterology. 2013;60:410–4.
- 17. Dalton RS, Velineni R, Osborne ME, et al. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Color Dis. 2012;14:567–71.
- Lai CL, Lai MJ, Wu CC, et al. Rectal cancer with complete clinical response after neoadjuvant hemoradiotherapy, surgery, or "watch and wait". Int J Color Dis. 2016;31:413–9.
- Lee SY, Kim CH, Kim YJ, et al. Oncologic outcomes according to treatment strategy in radiologic complete responders after neoadjuvant chemoradioation for rectal cancer. Oncology. 2015;89:311–8.
- Li J, Liu H, Yin J, et al. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. Oncotarget. 2015;6:4235–61.
- Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633–40.

- Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (theOnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174–83.
- Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256:965–72.
- Yeom SS, Lee SY, Kim CH, et al. Non-operative treatment outcome for rectal cancer patient with clinical complete response after neoadjuvant chemoradiotherapy. Asian J Surg. 2019;42:823–31.
- Wang XH, Zhou JC, Zhang S, et al. Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy. Chin J Gastrointest Surg. 2020;23(3):266–73.
- Wells GA, Shea B, O'Connell D, et al. The Newcastle-Patent Scale (NOS) for assessing the quality of nonrandomised studies in meta- analyses. Ottawa Hospital Research Institute Web Site. http://www ohri ca/ programs/clinical epidemiology/oxford.asp. Accessed October 2017;25.
- Oldani A, Cesana G, Uccelli M, et al. Surgical outcomes of rectal resection: our 10 years experience. J Laparoendosc Adv Surg Tech A. 2019;29:820–5.
- Petrelli F, Sgroi G, Sarti E, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64.
- Pozo ME, Fang SH. Watch and wait approach to rectal cancer: a review. World J Gastrointest Surg. 2015. 27;7(11):306-312.
- Du D, Su Z, Wang D, et al. Optimal interval to surgery after neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer. 2018;17(1):13–24.
- Goodman KA. Total neoadjuvant therapy for rectal cancer. Cancer Radiother. 2018;22(5):459–65.
- Lu HT, Liu X, Shi G, et al. A comparative study of the minimal invasive surgery and radical surgery in low rectal cancer with almost-cCR (near-cCR) after neoadjuvant therapy. Modern Oncology. 2019;27:2900–4.
- Lin GP, Lee KD, Wang JY, et al. Status for clinically complete remission rectal cancer after concomitant chemo-radiotherapy in Taiwan. Asian J Surg. 2018; 41:203–06.
- Arauio RO, Valadão M, Borges D, et al. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol. 2015;41:1456–63.
- Smith RK, Fry RD, Mahmoud NN, et al. Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. Int J Color Dis. 2015;30: 769–74.
- Li SJ, Wang L, Zhang XY, et al. Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy. Zhonghua Wei Chang Wai Ke Ze Zhi. 2019;22:648–55.
- Feeney G, Sehgal R, Sheehan M, et al. Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol. 2019;25(33):4850–69.
- Gérard JP, Barbet N, Gal J, et al. Planned organ preservation for early T2-3 rectal adenocarcinoma: a French, multicentre study. Eur J Cancer. 2019;108: 1–16.
- Rullier E, Rouanet P, Tuech JJ, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390:469–79.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

